FLUNIVAC

InFLUenza virus UNIVersal VACcine development program

Coordinatore	ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM    more  Organization address address: 's Gravendijkwal 230 city: ROTTERDAM postcode: 3015CE contact info Titolo: Mr. Nome: Wim Cognome: Leep Email: send email Telefono: +31 10 7043451 Fax: +31 10 7044760
Nazionalità Coordinatore	Netherlands [NL]
Totale costo	6˙973˙633 €
EC contributo	5˙066˙881 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2013-INNOVATION-1
Funding Scheme	CP-FP
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-10-01   -   2017-09-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM  Organization address address: 's Gravendijkwal 230 city: ROTTERDAM postcode: 3015CE contact info Titolo: Mr. Nome: Wim Cognome: Leep Email: send email Telefono: +31 10 7043451 Fax: +31 10 7044760	NL (ROTTERDAM)	coordinator	1˙218˙786.00
2	ARTEMIS ONE HEALTH RESEARCH BV  Organization address address: JENALAN 18C city: UTRECHT postcode: 3584CK contact info Titolo: Prof. Nome: Eric Cognome: Claassen Email: send email Telefono: +31 6 20443098	NL (UTRECHT)	participant	918˙211.00
3	Q-BIOLOGICALS NV  Organization address address: TECHNOLOGIEPARK 4 city: GENT postcode: 9052 contact info Titolo: Dr. Nome: Annie Cognome: Van Broekhoven Email: send email Telefono: +32 475966070	BE (GENT)	participant	606˙002.00
4	PROBIOGEN AG  Organization address address: Goethestrasse 54 city: Berlin postcode: 13086 contact info Nome: Andrea Cognome: Hauptmann Email: send email Telefono: +49 30 924006148 Fax: 493092000000	DE (Berlin)	participant	586˙050.00
5	LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN  Organization address address: GESCHWISTER SCHOLL PLATZ 1 city: MUENCHEN postcode: 80539 contact info Titolo: Prof. Nome: Gerd Cognome: Sutter Email: send email Telefono: +4989 21802514 Fax: +4989 218016576	DE (MUENCHEN)	participant	526˙360.00
6	VIB  Organization address address: Rijvisschestraat 120 city: ZWIJNAARDE - GENT postcode: 9052 contact info Nome: Rik Cognome: Audenaert Email: send email Telefono: 3292446611 Fax: 3292446610	BE (ZWIJNAARDE - GENT)	participant	520˙260.00
7	Aimm Therapeutics BV  Organization address address: Meibergdreef 45 city: Amsterdam postcode: 1105BA contact info Titolo: Dr. Nome: Willem Cognome: Van Oort Email: send email Telefono: +31 20 5662145 Fax: +31 20 5669081	NL (Amsterdam)	participant	394˙662.00
8	NOVAVAX AB  Organization address address: KUNGSGATAN 109 city: UPPSALA postcode: 753 18 contact info Titolo: Mr. Nome: Erik Cognome: Bergman Email: send email Telefono: +4618 161729 Fax: +4618 161701	SE (UPPSALA)	participant	296˙550.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

Effectively protecting the general population from seasonal and pandemic influenza has proven to be a challenge, since influenza viruses continue to escape from and evade immunity. Current influenza vaccines fail to provide long-lasting and broad protection against multiple strains of influenza. For the development of a universal influenza vaccine, we have to “do better than Nature”, since even natural influenza virus infections fail to induce broad protective immunity. To induce broad-protective and long-lasting immunity an influenza vaccine should therefore be directed to conserved viral proteins or regions thereof that are insufficiently exposed upon natural infection. FLUNIVAC is a SME-targeted collaborative research project that aims to develop a candidate influenza vaccine based on recombinant MVA expressing both antibody and T-cell response-inducing proteins, ready to commence Phase I clinical trials within 4 years. We will generate recombinant MVAs that express nine conserved (regions of) influenza A virus proteins (surface proteins HA, NA, M2e, internal proteins M1, NP, NS1, and the polymerase proteins PB1, PB2, PA). These proteins are targets for both antibody and T-cell mediated immune responses, since the induction of solely one of both affords only modest protection against infection with influenza viruses of heterologous subtypes. These recombinant MVAs will be tested for their capacity to induce the desired broad-protective immune response individually and in selected combinations in vivo. In parallel, MVA-induced immune responses will be tested for their longevity and boostability as compared with those induced with adjuvanated vaccine preparations. Furthermore, the MVA platform will be optimized in terms of: i) kinetics and extent of protein-expression of the MVA vector to optimally activate the respective arms of the immune system; ii) a viable unified production process, independent of embryonated chicken eggs, will be designed and implemented.